Skip to content
value.today
CellaVision AB (publ) logo

CellaVision AB (publ)

CEVI.ST
$490 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$77 M
For year ending December-2025
Net income
$16 M
20.2% margin
Official annual report (ESEF)
Employees
—

CellaVision AB (publ) in brief

CellaVision AB (publ) is a listed company in the Medical Devices industry, based in Sweden. It was founded in 1994. Its last known market value was $490 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $77 M and a net profit of $16 M, about 20 cents of profit for every dollar of sales. Its shares trade under the symbol CEVI.ST (Stockholm).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CellaVision AB (publ)

CellaVision AB (publ) is a provider of digital solutions company for medical microscopy in the field of haematology. The headquarters is in Sweden.

CellaVision AB (publ) company annual revenue was 639 million SEK, annual net income was 118 million SEK as on Dec-2022.

CellaVision AB (publ) timeline

2 events, 1994–2014
  1. 1994
  2. 🏁
    · approximate
    Founded
  3. 2014
  4. •
    Legal Entity Identifier issued
    LEI 529900IUBZBZ0HXFJ114 registered.

Events of CellaVision AB (publ) from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$239 M$478 M$718 M$957 M20202021202220232024

World rank over time

▼ down 4,513 places since 2020
2020-01-01: #8221#8,22120202021-01-01: #8435#8,43520212022-01-07: #10304#10,30420222022-12-25: #11997#11,99720222023-07-30: #12747#12,74720232024-01-05: #12734#12,7342024

Rank in Sweden: #118 (Jan 2020) · #141 (Jan 2021) · #171 (Jan 2022) · #162 (Dec 2022) · #156 (Jul 2023) · #166 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
—
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
20.2%
Operating margin
26.6%
Return on equity
16.2%
Liabilities / assets
18.9%
Revenue growth
+12.9%
R&D / revenue
12.9%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2024: revenue $68M, net income $13M$68MFY24Fiscal year ending Dec 2025: revenue $77M, net income $16M$77MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$77M+12.9%$21M$16M20.2%
Dec 2024$68M—$17M$13M19.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$20M$2M$19M$0.65—
Dec 2024$19M$1M$18M$0.56—

Annual results

Revenue
$77 M
Operating income
$21 M
Net income
$16 M

For year ending December-2025 · source: official annual report (ESEF)

Balance sheet

Total assets
$119 M
Total liabilities
$23 M
Total equity
$96 M

As of December-2025

Mutual funds holding CellaVision AB (publ)#

41 funds in 2 countries hold shares worth $63 M. Since their previous reports 11 added shares and 15 sold, buying $1 M net. By country: Sweden 25 ($59 M), USA 16 ($4 M).
Mutual funds holding CellaVision AB (publ)
FundSharesValueOf the companyOf the fundChange in sharesReport
🇸🇪 AMF Aktiefond SmåbolagAMF Fonder AB804,300$11 M—0.86%+26%Jun 30, 2026
🇸🇪 SEB Sverigefond Småbolag Chans/RiskSEB Funds AB784,678$11 M—0.50%no changeJun 30, 2026
🇸🇪 Case All Star SmåbolagCase Kapitalförvaltning AB698,455$10 M—2.9%no changeJun 30, 2026
🇸🇪 Swedbank Robur ExportfondSwedbank Robur Fonder AB499,396$7 M—0.62%no changeJun 30, 2026
🇸🇪 Länsförsäkringar Småbolag Sverige VisionLänsförsäkringar Fondförvaltning AB360,587$5 M—0.54%no changeJun 30, 2026
🇸🇪 Handelsbanken Norden Index CriteriaHandelsbanken Fonder AB307,023$4 M—0.11%no changeJun 30, 2026
🇸🇪 Lannebo Hälsa och Ny TeknikLannebo Kapitalförvaltning AB187,872$3 M—4.3%+90%Jun 30, 2026
🇸🇪 Handelsbanken Sverige Index CriteriaHandelsbanken Fonder AB141,242$2 M—0.02%no changeJun 30, 2026
🇺🇸 Harding Loevner International Small Companies PortfolioHarding Loevner LP100,233$2 M—0.89%−10%Jul 31, 2026
🇸🇪 SEB Sverige IndexnäraSEB Funds AB107,514$2 M—0.02%+2.1%Jun 30, 2026
🇸🇪 PLUS Mikrobolag Sverige IndexISEC Services AB59,809$1 M—2.0%newJun 30, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP52,803$1 M—<0.01%−3.9%Jul 31, 2026
🇸🇪 SEB Sverige IndexfondSEB Funds AB52,445$1 M—0.03%no changeJun 30, 2026
🇸🇪 Länsförsäkringar Mix VisionLänsförsäkringar Fondförvaltning AB51,017$1 M—0.05%+4.3%Jun 30, 2026
🇸🇪 Storebrand Sverige PlusStorebrand Asset Management AS44,590$1 M—0.03%no changeJun 30, 2026
🇸🇪 Skandia Sverige ExponeringSkandia Fonder AB43,359$1 M—0.03%no changeJun 30, 2026
🇸🇪 Storebrand Sverige Småbolag PlusStorebrand Asset Management AS24,123$0 M—0.10%+6.6%Jun 30, 2026
🇸🇪 Storebrand SverigeStorebrand Asset Management AS22,645$0 M—0.02%no changeJun 30, 2026
🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP19,959$0 M—<0.01%+86%Jul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP18,723$0 M—<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.20,251$0 M—0.03%+1.0%Jun 30, 2026
🇸🇪 Skandia BalanseradSkandia Fonder AB12,517$0 M—0.01%no changeJun 30, 2026
🇸🇪 Lannebo Marknad Sverige BredLannebo Kapitalförvaltning AB11,500$0 M—0.03%no changeJun 30, 2026
🇸🇪 Skandia Världen SverigeSkandia Fonder AB9,373$0 M—0.02%no changeJun 30, 2026
🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc.7,353$0 M—<0.01%−0.1%Jun 30, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP5,125$0 M—<0.01%−46%Jul 31, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP3,880$0 M—<0.01%−4.0%Jul 31, 2026
🇸🇪 Kvartil Nordiska Småbolag+ FaktorQuartile Fonder AB3,090$0 M—0.13%+94%Jun 30, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP2,468$0 M—<0.01%+13%Jul 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP2,319$0 M—<0.01%no changeJul 31, 2026
🇸🇪 Småbolag Sverige ExponeringSkandia Fonder AB2,087$0 M—0.08%+11%Jun 30, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC1,841$0 M—<0.01%no changeJun 30, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP1,475$0 M—<0.01%no changeJul 31, 2026
🇸🇪 Skandia FörsiktigSkandia Fonder AB1,206$0 M—0%no changeJun 30, 2026
🇸🇪 Skandia Mix 100 ExponeringSkandia Fonder AB1,087$0 M—0.01%no changeJun 30, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC999$0 M—0.01%no changeJun 30, 2026
🇸🇪 Skandia Mix 60 ExponeringSkandia Fonder AB891$0 M—0%no changeJun 30, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation841$0 M—<0.01%no changeJun 30, 2026
🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc.536$0 M—<0.01%−2.2%Jun 30, 2026
🇸🇪 Avanza SwedenAvanza Fonder AB314$0 M—0.01%—Jun 30, 2026
🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC246$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 41 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

CellaVision AB (publ) scorecard#

Passes 5 of the 5 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth2 of 2
    • ✓Revenue grew in the newest year12.9%Revenue up 12.9% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year0.65 vs 0.56Diluted EPS 0.65 in fiscal 2025 against 0.56 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 3
    • ✓Profitable in the newest year$16 MNet income $16 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median26.6%26.6% against Medical Devices's median of -8.2% (86 companies).
    • ✓Return on equity above 15%18.3%18.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (esef), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from CellaVision AB (publ)'s statements, beside the median of Medical Devices.

CellaVision AB (publ): main financial ratios in 2025
Ratio2025Median of peers
Operating margin26.6%-8.2%
Net margin20.2%-10.4%
Return on equity18.3%-16.8%
Revenue growth12.9%10.4%
Free cash flow margin23.9%-1.9%

4of 6on the Piotroski tests of financial strength

CellaVision AB (publ): financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in SEK millions; per-share figures in SEK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CellaVision AB (publ): statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue759723677639566471
Cost of revenue239236214201173158
Gross profit520487463438392313
Research and development988783896451
General and administrative908576746351
Operating income202178167158163110
Income before tax194177164148158112
Income tax413634303323
Net income including minority interests15314113011812589
Earnings per share, basic6.425.905.464.96——
Earnings per share, diluted6.425.905.464.96——
Shares, weighted average (basic)242424242424
Dividends per share2.502.252.25———
Balance sheet
Cash and cash equivalents188149122108130102
Receivables141129118127119112
Inventory11212512614311584
Current assets441403366377365298
Goodwill121128124124114112
Non-current assets654610563515460370
Total assets1,0951,013929892825668
Current liabilities111109119133135104
Long-term debt121329609687
Non-current liabilities968893117147134
Retained earnings865772685608537430
Shareholders' equity888816716642543430
Total equity888816716642543430
Total liabilities and equity1,0951,013929892825668
Shares outstanding242424242424
Cash-flow statement
Cash from operating activities20119819613716071
Capital expenditure−19−12−32−23−14−8.1
Intangible assets bought——0−0.2−32−0.1
Acquisitions, net of cash acquired————0−1.3
Cash from investing activities−86−76−86−70−84−35
Debt issued————213.0
Debt repaid−1.6−29−31−32−40−29
Dividends paid−60−54−54−48−180
Cash from financing activities−75−95−97−90−48−35
Exchange-rate effect on cash−1.00.4−0.30.91.1−1.0
ReportESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How CellaVision AB (publ) compares in Medical Devices

  • Revenue$77 M · higher than 35% of 155
  • Net margin20.2% · higher than 90% of 144
  • Revenue growth12.9% · higher than 54% of 104

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
CellaVision AB (publ)🇸🇪$490 M—20.2%+12.9%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 15, 2026

Figures from Official annual report (ESEF), Wikidata, value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CellaVision AB (publ)? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CellaVision AB (publ)'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CellaVision AB (publ)? Suggest a correction